Introduction to Sitagliptin API
Sitagliptin API (Active Pharmaceutical Ingredient) is a widely used pharmaceutical raw material for the production of medicines intended to support blood glucose management in adults with type 2 diabetes. It belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, which helps improve the body’s natural ability to regulate blood sugar levels. Due to its proven efficacy, safety profile, and global acceptance, Sitagliptin API is extensively manufactured and supplied to pharmaceutical companies worldwide for tablet formulation and contract manufacturing.
Key Chemical Information of Sitagliptin API
Understanding the chemical characteristics of Sitagliptin API is essential for pharmaceutical manufacturers and formulation developers.
- Generic Name: Sitagliptin
- CAS Number: 486460-32-6
- Molecular Formula: C₁₆H₁₅F₆N₅O
- Molecular Weight: 407.31 g/mol
- API Category: DPP-4 Inhibitor
- Dosage Form: Primarily used in tablet formulations
- Storage Condition: Store in a cool, dry place away from moisture and direct sunlight.
Its stable chemical profile and compatibility with modern manufacturing processes make it a preferred API for antidiabetic formulations.
Reliable Sitagliptin API Manufacturer Worldwide
Sitagliptin works by inhibiting the DPP-4 enzyme, which increases the levels of incretin hormones in the body. These hormones stimulate insulin release when blood glucose levels are elevated and reduce glucagon secretion from the pancreas. This dual action helps improve glycemic control without causing significant fluctuations in blood sugar levels. Because of this targeted mechanism, Sitagliptin has become one of the most commonly prescribed DPP-4 inhibitors in global diabetes management.
Pharmaceutical Applications of Sitagliptin API
Sitagliptin API is primarily utilized in the manufacturing of oral antidiabetic tablets. It may be formulated as a standalone product or combined with other antidiabetic APIs such as Metformin to provide comprehensive glucose management. Pharmaceutical manufacturers value Sitagliptin API for its consistent quality, formulation flexibility, and suitability for large-scale commercial production.
Global Market Demand for Sitagliptin API
The increasing prevalence of type 2 diabetes across developed and emerging economies has significantly boosted demand for Sitagliptin API. Rising healthcare awareness, improved access to diabetes treatment, expanding generic medicine markets, and government initiatives for chronic disease management continue to drive global consumption. Countries across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa are witnessing growing demand for reliable API suppliers capable of maintaining international quality standards and uninterrupted supply chains.
Quality Standards and Regulatory Compliance
High-quality Sitagliptin API should be manufactured under stringent Good Manufacturing Practices (GMP) with comprehensive quality control procedures. Each production batch undergoes extensive testing for identity, assay, purity, impurities, residual solvents, particle size, and microbiological quality. Complete documentation, including Certificate of Analysis (COA), Material Safety Data Sheet (MSDS), and other regulatory documents, supports pharmaceutical registration and global distribution requirements.
Why Choose Amber Lifesciences for Sitagliptin API?
Amber Lifesciences is a trusted manufacturer, exporter, and global supplier of high-quality pharmaceutical APIs. The company focuses on delivering consistent product quality, regulatory compliance, and dependable international supply. With advanced manufacturing capabilities, stringent quality assurance systems, competitive pricing, and efficient logistics support, Amber Lifesciences serves pharmaceutical manufacturers across regulated and emerging markets. The company is committed to building long-term partnerships through reliable service, technical expertise, and customer-focused solutions.
Reliable Sitagliptin API Manufacturer Worldwide
Sitagliptin API remains one of the leading active pharmaceutical ingredients for the treatment of type 2 diabetes due to its established therapeutic value, reliable performance, and growing global demand. Pharmaceutical companies seeking a dependable source of high-quality Sitagliptin API benefit from selecting experienced manufacturers that emphasize quality, compliance, and uninterrupted supply. Amber Lifesciences continues to support global pharmaceutical companies with premium-grade Sitagliptin API backed by quality assurance and professional customer service.
Frequently Asked Questions (FAQs)
1. What is Sitagliptin API?
Sitagliptin API is the active pharmaceutical ingredient used to manufacture medicines for managing type 2 diabetes.
2. Which therapeutic class does Sitagliptin belong to?
It belongs to the DPP-4 (Dipeptidyl Peptidase-4) inhibitor class.
3. What is the CAS number of Sitagliptin API?
The CAS number is 486460-32-6.
4. What dosage forms commonly use Sitagliptin API?
It is primarily used in oral tablet formulations.
5. Can Sitagliptin API be combined with other APIs?
Yes. It is frequently formulated with Metformin and other antidiabetic ingredients.
6. Which industries purchase Sitagliptin API?
Pharmaceutical manufacturers, formulation companies, contract manufacturing organizations (CMOs), and generic medicine producers.
7. What quality documents are generally available?
Common documents include COA, MSDS, manufacturing information, and quality-related regulatory documentation.
8. How should Sitagliptin API be stored?
It should be stored in a cool, dry environment away from excessive heat, moisture, and direct sunlight.
9. Why is global demand for Sitagliptin API increasing?
The growing incidence of type 2 diabetes, expansion of generic medicines, and increased healthcare access continue to drive worldwide demand.
10. Why choose Amber Lifesciences for Sitagliptin API?
Amber Lifesciences offers high-quality API manufacturing, consistent quality standards, regulatory support, competitive pricing, and reliable global supply for pharmaceutical companies.
